Nutex Health (NASDAQ:NUTX - Get Free Report) is anticipated to announce its earnings results after the market closes on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $81.13 million for the quarter.
Nutex Health Trading Up 9.4 %
Shares of NASDAQ NUTX traded up $5.00 during trading on Friday, hitting $58.17. 41,913 shares of the company traded hands, compared to its average volume of 49,318. The company has a quick ratio of 1.74, a current ratio of 1.77 and a debt-to-equity ratio of 3.36. The firm has a market capitalization of $316.27 million, a P/E ratio of -6.20 and a beta of 0.01. The company has a 50-day moving average price of $50.00 and a 200-day moving average price of $35.53. Nutex Health has a 1 year low of $4.16 and a 1 year high of $69.45.
Analyst Upgrades and Downgrades
Separately, Maxim Group upped their price target on Nutex Health from $50.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th.
Get Our Latest Stock Analysis on Nutex Health
Hedge Funds Weigh In On Nutex Health
A hedge fund recently raised its stake in Nutex Health stock. Bank of America Corp DE boosted its position in Nutex Health Inc. (NASDAQ:NUTX - Free Report) by 6,590.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,074 shares of the company's stock after buying an additional 2,043 shares during the quarter. Bank of America Corp DE's holdings in Nutex Health were worth $66,000 at the end of the most recent quarter. 5.32% of the stock is currently owned by institutional investors.
About Nutex Health
(
Get Free Report)
Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.
Featured Articles
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
